HER2-low breast cancerHER2-lowBreast CancerHER2-0 tumorsNIH NCItrastuzumab deruxtecanThe Harvard Ludwig CenterDana-Farber Cancer InstituteSusan G. Komen Foundation
…), have transformed the therapeutic landscape for patients with HER2-low breast cancer. However, the biological basis distinguishing HER2-low (IHC 1+ …